The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

BHVN INVESTORS: Kirby McInerney LLP Reminds Biohaven Ltd. Investors of Important Deadline and Encourages Investors to Contact the Firm

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Connecticut on behalf of those who acquired Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) securities during the period of March 24, 2023 through May 14, 2025, inclusive (“the Class Period”). Investors have until September 12, 2025 to apply to the Court to be ap-pointed as lead plaintiff in the lawsuit.

[LEARN MORE ABOUT THE CLASS ACTION]

The lawsuit was filed on behalf of investors who acquired Biohaven securities from March 24, 2023 through May 14, 2025, inclusive (“the Class Period”). Investors have until September 12, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit claims that Biohaven made false or misleading statements, or failed to disclose that: (i) it exaggerated the likelihood that troriluzole would receive regulatory approval to treat SCA, as well as the strength of the supporting data; and (ii) it also overstated the effectiveness and clinical potential of BHV-7000 as a treatment for bipolar disorder.

If you purchased or otherwise acquired Biohaven securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.